Erinacine S treatment also significantly upregulated the expression of TRAIL, TNFR1, and DR5 proteins, concurrently downregulating the CXCR4/PI3K/AKT/ERK and NFκB/HIF1α/P-gp signaling pathways in chemoresistant human CRC cells. This evidence concerns the gene CXCR4 and colorectal carcinoma.